Mechanisms of uptake of gallium by human neuroblastoma cells and effects of gallium and aluminum on cell growth, lysosomal protease, and choline acetyl transferase activity.
We have studied the uptake and removal of gallium, used as an analogue of aluminum, and the effects of aluminum itself on cultured human neuroblastoma cells treated with soluble metal complexes. The prohibitively high cost of measurement of the only available radioisotope of aluminum (26Al) precluded its usage, and so we considered that gallium, which is chemically extremely similar, would be the most suitable model. Gallium has been used thus in a number of previous biological studies and has been found to behave like aluminum in many respects. We have previously shown that Al-EDTA treatment results in uptake of aluminum and expression of hyperphosphorylated tau, a key component of Alzheimer's disease paired helical filaments. Here we demonstrate that gallium uptake can occur by two separate methods, both leading to physiologically relevant intracellular metal concentrations. Uptake from medium containing bovine transferrin occurred mainly by pinocytosis, but in the presence of human transferrin (hTf), uptake by transferrin-mediated endocytosis occurred also, despite a very low level of hTf saturation, indicating that Tf-mediated uptake is a very effective method of Ga internalization. The intracellular gallium is relatively stable, though partially removable by (1 mM) EDTA, desferrioxamine, or 1,2-dimethyl-3-hydroxypyrid-4-one. Aluminum and gallium treatment were found to increase the overall activity of lysosomal proteases, enzymes implicated in amyloid precursor protein cleavage. No effects were detected on choline acetyl transferase activity, cell growth, or tritiated thymidine incorporation or on the structure of the cells, as judged by light or electron microscopy.
Molecular Neurobiology Laboratory, Department of Optometry and Vision Sciences, UMIST, Sackville Street, Manchester, M60 1QD, United Kingdom.
C B
CB
Dobson
J
J
Graham
R F
RF
Itzhaki
D000535:Aluminum / Q000494:pharmacology*; D000818:Animals; D001692:Biological Transport; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002614:Chelating Agents / Q000494:pharmacology; D002795:Choline O-Acetyltransferase / Q000187:drug effects / Q000378:metabolism*; D002951:Citrates / Q000493:pharmacokinetics; D004492:Edetic Acid / Q000494:pharmacology; D010450:Endopeptidases / Q000378:metabolism*; D005708:Gallium / Q000493:pharmacokinetics* / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008247:Lysosomes / Q000201:enzymology*; D009447:Neuroblastoma / Q000378:metabolism*; D010873:Pinocytosis; D014168:Transferrin / Q000494:pharmacology / Q000502:physiology; D014407:Tumor Cells, Cultured
D002614:Chelating Agents; D002951:Citrates; D014168:Transferrin; D004492:Edetic Acid; D005708:Gallium; D000535:Aluminum; D002795:Choline O-Acetyltransferase; D010450:Endopeptidases; C103850:gallium citrate